Screener
Castle Biosciences CSTL Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Castle Biosciences’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-031263
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Net gains (losses) on equity securities | 2,022 | (1,425) |
| Interest expense | (134) | (17) |
| Other loss | (439) | — |
| Loss before income taxes | (14,413) | (26,271) |
| Income tax expense (benefit) | 109 | (423) |
| Net loss | $(14,522) | $(25,848) |
| Loss per share, basic and diluted | $(0.49) | $(0.90) |
| Weighted-average shares outstanding, basic and diluted | 29,889 | 28,609 |
Item 1. Financial Statements.
FAQ
- What is Castle Biosciences's net income?
- Castle Biosciences (CSTL) reported net income of -$14.52M in Q1 2026.
- How has Castle Biosciences's net income changed year-over-year?
- Castle Biosciences's net income increased by 43.8% year-over-year, from -$25.85M to -$14.52M.
- What is the long-term trend for Castle Biosciences's net income?
- Over 4 years (2021 to 2025), Castle Biosciences's net income has grown at a -6.3% compound annual growth rate (CAGR), from -$31.29M to -$24.16M.
- What does net income mean?
- Net income as the starting point for the indirect method operating cash flow reconciliation.
Ask your AI about Castle Biosciences's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude